Overview
Sweden drug delivery firm reported Q4 revenue up significantly yr/yr
Company announced license and option agreement with Moderna
Company converted 8.5 mln warrants into shares, raising SEK 17 mln
Outlook
Nanexa sees favorable conditions for 2026 due to Moderna agreement
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
SEK 30.09 mln
Q4 EPS
SEK 0.10
Q4 Net Income
SEK 16.04 mln
Q4 EBIT
SEK 16.67 mln
Analyst Coverage
The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 14 three months ago
Press Release: ID:nMFN95N9Bn
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
